Adia Nutrition to Feature WWE Star in Stem Cell Doc

A documentary is in production detailing the recovery of professional wrestler Jeff Sciullo, also known as Elias and Elijah in WWE and TNA respectively, from a tricep injury sustained in June 2025. The film will chronicle his treatment using Adia Med’s AdiaVita, a stem cell protocol, and is slated for release between February and March 2026.

The Road to Recovery

Jeff Sciullo suffered a tricep injury during a live WWE Wrestling match, as observed by Dr. Asa Andrew, who served as the ringside physician. The documentary, a part of “Making Rounds with Dr. Asa” series on The Dr. Asa Network, will offer an inside look at Sciullo’s rehabilitation process. Dr. Asa Andrew, medical director and head ringside physician for TNA Wrestling, and host of “The Dr. Asa Show,” will be filming behind-the-scenes footage.

AdiaVita Protocol Details

Adia Med’s AdiaVita treatment involves a high-potency stem cell product. According to Adia Nutrition Inc., each dose delivers over 100 million umbilical cord-derived stem cells and more than 3 trillion exosomes. The company highlights this concentration as a key factor in Sciullo’s recovery, aiming to demonstrate the potential for rapid tissue repair and reduced inflammation.

Did You Know? Dr. Asa Andrew was the ringside physician present when Jeff Sciullo sustained his tricep injury.

Multiplatform Release and Business Implications

The documentary is planned for distribution across a wide range of platforms, including radio, television, podcasts, and social media, through The Dr. Asa Network. Adia Nutrition Inc. intends to leverage this exposure to encourage interest in clinic licensing and strategic partnerships for its regenerative therapies. Larry Powalisz, CEO of Adia Nutrition, stated the film will highlight the “real-world results” of the AdiaVita treatment.

Expert Insight: The decision to document a high-profile athlete’s recovery using a specific regenerative therapy represents a strategic effort to raise awareness and potentially drive demand for the treatment. The multiplatform distribution strategy suggests a broad outreach effort aimed at both healthcare professionals and the general public.

Sciullo himself expressed optimism about the treatment, stating that Adia Med’s AdiaVita enabled a faster-than-expected return to wrestling. He emphasized the significance of Dr. Asa’s involvement, given his firsthand knowledge of the injury’s severity and the subsequent recovery process.

About Adia Nutrition Inc.

Adia Nutrition Inc., based in Winter Park, Florida, is a publicly traded company (OTCQB: ADIA) focused on advancing healthcare through innovation. The company’s activities include sales of stem cell and regenerative products, operation of Adia Med clinics specializing in orthopedic and pain management, and investment in aligned businesses like Cement Factory LLC.

Frequently Asked Questions

What is Adia Nutrition (ADIA) announcing about Jeff Sciullo’s recovery in January 2026?

Adia Nutrition announced a documentary showing Jeff Sciullo’s recovery after a June 2025 tricep injury. According to Adia Nutrition, the film documents his treatment with AdiaVita and will air on The Dr. Asa Network in February–March 2026 across multiple platforms.

What does Adia Nutrition say is in an AdiaVita dose for ADIA investors?

Adia Nutrition describes an AdiaVita dose as containing over 100 million umbilical cord-derived stem cells and more than 3 trillion exosomes. According to Adia Nutrition, those specifications are presented in the documentary to illustrate the product’s regenerative concentration.

When and where will the Adia Nutrition (ADIA) documentary premiere?

The documentary is scheduled to premiere between February and March 2026 on The Dr. Asa Network. According to Adia Nutrition, the release will span radio, television, podcast, and social media outlets for broad multiplatform reach.

As regenerative therapies continue to evolve, how might increased visibility through media like this documentary influence patient expectations and the adoption of these treatments?